ST中基(000972.SZ)擬投資5億元設立兩家全資子公司
格隆匯7月28日丨ST中基(000972.SZ)公佈,鑑於公司擬實施的非公開發行股票的募集資金投資項目的需要,為達成經營業務轉型升級目的,增加盈利能力,更好保護股東權益尤其是中小投資者合法權益,實現持續穩定健康發展,公司擬投資設立兩家全資子公司:中基中醫藥科技(新疆)有限公司(以下簡稱“中基中醫藥”)及中基應急醫療(新疆)有限公司(以下簡稱“中基應急醫療”)。註冊資本均為人民幣2.5億元。
設立中基中醫藥的目的:中醫藥產業現代化—新疆道地藥材及飲片產業化基地建設項目。設立中基應急醫療的目的:常態化防疫專項—新疆應急醫療防疫物資生產基地建設項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.